US LNG exports surge but will buyers in China turn up?
ZUG, Switzerland and BOSTON - CRISPR Therapeutics (NASDAQ:CRSP), a pioneer in gene-based medicine, has announced that Chief Operating Officer Julianne Bruno is set to leave the company on April 11, 2025, to explore new opportunities. Bruno’s departure marks the end of a six-year tenure with the biopharmaceutical firm, during which she played a pivotal role in the development of its hematology and oncology programs and the implementation of significant initiatives aimed at enhancing the company’s operational framework. The company, currently valued at $3.4 billion, maintains a strong financial position with more cash than debt on its balance sheet, according to InvestingPro data.
Chairman and CEO of CRISPR Therapeutics, Samarth Kulkarni, Ph.D., commended Bruno for her significant contributions to the company’s leadership team and wished her success in her future endeavors. While the company’s stock has shown significant volatility, six analysts have recently revised their earnings expectations upward for the upcoming period, as reported by InvestingPro.
CRISPR Therapeutics has been at the forefront of gene editing technology since its establishment over ten years ago. The company has been recognized for its groundbreaking work with the CRISPR/Cas9 gene-editing platform, which has been celebrated with a Nobel Prize and has shown significant clinical promise. The company’s achievements include the historic approval of the first CRISPR-based therapy, CASGEVY® (exagamglogene autotemcel [exa-cel]), which, as of late 2023, is available in multiple countries for the treatment of sickle cell disease and transfusion-dependent beta thalassemia. With a current ratio of 22.07, the company maintains excellent liquidity to fund its innovative research and development initiatives.
With a diverse portfolio covering hemoglobinopathies, oncology, regenerative medicine, cardiovascular, autoimmune, and rare diseases, CRISPR Therapeutics continues to advance in the biopharmaceutical industry. The company has also established strategic partnerships to bolster its research and development efforts, including a collaboration with Vertex Pharmaceuticals.
CRISPR Therapeutics AG, with its headquarters in Zug, Switzerland, operates its wholly-owned U.S. subsidiary and R&D facilities out of Boston, Massachusetts, and San Francisco, California. The information about Julianne Bruno’s resignation is based on a press release statement from the company.
In other recent news, CRISPR Therapeutics has been the subject of multiple analyst updates and developments. Citi analysts have reduced their price target for CRISPR Therapeutics to $82 while maintaining a Buy rating, citing the company’s expanding treatment centers and an anticipated catalyst-rich year in 2025. Meanwhile, Evercore ISI has upgraded CRISPR Therapeutics to an Outperform rating, raising the price target from $60 to $99. This upgrade is based on the potential of the company’s in vivo programs, CTX320 and CTX310, and a strong cash reserve of $1.9 billion.
On the other hand, Stifel has lowered its price target to $49, maintaining a Hold rating due to cautious expectations regarding the market uptake of Casgevy, CRISPR’s gene editing therapy. Stifel’s analysis highlights stringent safety requirements for in vivo gene editing treatments. TD Cowen has also adjusted its stance, upgrading CRISPR Therapeutics from Sell to Hold, with a steady price target of $35, acknowledging reduced downside risk.
These recent developments reflect varied analyst perspectives on CRISPR Therapeutics’ strategic direction and pipeline potential. The market will be observing CRISPR’s management decisions closely, especially concerning Casgevy’s launch and pipeline advancements.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.